Skip to Primary Navigation

Skip to main content

FDA requires class-wide GLP-1 label update to include risk of blindness

The warning for NAION risk applies to all GLP-1 medications, including popular weight loss drugs Ozempic, Wegovy, Mounjaro, and Zepbound.

Kevin Kinsella

A photo of an unlabeled Ozempic applicator against a black background.
Photo: Steve Christo -Corbis/Corbis via Getty Images
Click to share on Facebook (Opens in new window/tab) Click to share on X (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

Citing an increased risk of a rare optic nerve condition that can result in permanent vision loss, the US Food and Drug Administration (FDA) has issued a drug-safety communication requiring safety labeling changes for the entire class GLP-1 receptor agonists (GLP-1 RA) drugs.

The warning applies to all GLP-1 medications,

, , , , , , , , ,

Get full access, free for a month

Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial
Sign in

What’s included:

  • Every new article, plus our 6,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience